Related Experiment Video

Updated: Jul 6, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for

J A McCubrey1, L S Steelman, S L Abrams

  • 1Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC 27858, USA. mccubreyj@ecu.edu

Leukemia
|March 14, 2008
PubMed

Insights

Targeting key cell survival pathways like Raf/MEK/ERK, PI3K/Akt, and Jak/STAT can inhibit leukemia growth and induce cancer cell death. This approach offers new therapeutic strategies for various hematopoietic disorders.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Key signaling pathways including Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR, and Jak/STAT are frequently hyperactivated in leukemia and other hematopoietic malignancies.
  • Mutations in cytokine receptors, chromosomal translocations, and other genetic alterations often drive the aberrant activation of these critical pathways.
  • Specific mutations, such as in Jak2 kinase, are prevalent in myeloproliferative disorders, highlighting the importance of these signaling cascades.

Purpose of the Study:

  • To review the mechanisms by which targeting the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR, and Jak/STAT pathways can suppress leukemogenesis and inhibit leukemia cell survival.
  • To explore the potential of combining conventional therapies with small molecule inhibitors of these pathways for enhanced efficacy in treating leukemia and other hematopoietic disorders.
  • To discuss emerging therapeutic strategies, including targeting the leukemia microenvironment and leukemia stem cells, as challenges and future directions in targeted leukemia therapy.

Main Methods:

  • This review synthesizes current literature on the role of specific signaling pathways in leukemia.
  • It examines the impact of inhibiting these pathways on cancer cell growth, survival, and apoptosis.
  • The review discusses the potential for combination therapies and novel targeting strategies.

Main Results:

  • Suppression of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR, and Jak/STAT pathways can effectively inhibit key survival networks crucial for leukemogenesis.
  • Targeting these pathways holds promise for inducing apoptosis and inhibiting the growth of leukemic cells.
  • Combination therapies involving pathway inhibitors may overcome resistance to existing treatments, including BCR-ABL inhibitors in chronic myelogenous leukemia.

Conclusions:

  • Targeting aberrant signaling pathways represents a promising therapeutic strategy for leukemia and other hematopoietic disorders.
  • Inhibiting these critical survival pathways can lead to reduced leukemic cell proliferation and increased apoptosis.
  • Future research should focus on combination therapies, targeting the leukemia microenvironment, and leukemia stem cells to improve treatment outcomes.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...